Mercator MedSystems

Mercator MedSystems develops micro-infusion technology for targeted drug and biologic delivery in interventional angiographic and catheterization lab settings. The company specializes in local, perivenous micro-infusion systems that enable efficient delivery of therapeutics directly to disease sites while minimizing off-target systemic effects. Their primary product platform, the Bullfrog microinfusion device, is designed for percutaneous delivery of anti-inflammatory agents in venous and arterial interventional procedures. Clinical applications include acute and chronic deep vein thrombosis (DVT) treatment to reduce post-thrombotic syndrome, and below-knee arterial revascularization. Mercator operates multiple Phase 2 clinical trials (DEXTERITY-AFP, DEXTERITY-SCI, TANGO) with FDA IND approval, UK MHRA, and Irish HPRA regulatory clearance. The company focuses on improving physician capability to match targeted therapeutics to specific vascular diseases through innovative micro-infusion delivery mechanisms that optimize drug efficacy at the site of pathology.